Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on aTyr Pharma yesterday and set a price target of $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faisal Khurshid has given his Buy rating due to a combination of factors including the promising outlook of aTyr Pharma’s EFZO-FIT trial. The insights from two MEDACorp KOLs involved in the trial suggest a significant potential for efzofitimod as a safe, steroid-sparing treatment for pulmonary sarcoidosis, provided the trial results are favorable. The KOLs’ anecdotal experiences, such as successful steroid tapering in some patients, add to the optimism, despite the trial’s constraints like blinding and a small sample size.
Furthermore, the KOLs expressed confidence in the trial’s operations and patient selection criteria, which were designed to minimize placebo effects. One KOL estimated a 65-70% probability of success (POS) for the trial, which is slightly more optimistic than Khurshid’s own 60% estimate. This positive sentiment, coupled with the high-risk, high-reward nature of the trial, underpins Khurshid’s Buy rating for aTyr Pharma, indicating a potentially attractive investment opportunity.
According to TipRanks, Khurshid is a 5-star analyst with an average return of 28.2% and a 61.47% success rate. Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, ANI Pharmaceuticals, and Spyre Therapeutics.
In another report released on August 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.